Pfizer-AstraZeneca deal could impact drug development
Video duration: 2:59
Pfizer's $106 billion bid for AstraZeneca has been making news this week both because of its size and suggestions that Pfizer is motivated by lower corporate tax rates overseas. But there's another question: how the possible merger might affect the development of new drugs. Shannon Pettypiece of Bloomberg joins Hari Sreenivasan for more.